Inhibrx Biosciences, Inc. (INBX) Stock

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences, Inc. is led by CEO Mark Paul Lappe, employs 156 people, headquartered in US, publicly traded since 2024.

Inhibrx Biosciences, Inc. (INBX) stock trades at $93.38 with a market capitalization of $1.37B. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.60, reflecting a net loss over the last twelve months, a negative price-to-book of -25.22, reflecting negative shareholders' equity, price-to-sales of 1254.83. Over the past 52 weeks the stock has ranged between $28.16 and $155.29, and currently trades 39.9% below its 52-week high.

On profitability, Inhibrx Biosciences, Inc. generates a return on equity (ROE) of -563.89% (not meaningful, as shareholders' equity is negative), return on capital employed of -101.31%, an operating margin of -13500.00%, a net profit margin of -14000.00%.

Official website: www.inhibrx.com

Inhibrx Biosciences, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Inhibrx Biosciences, Inc. reported revenue of $7.0M rising to $1.0M, a change of -85.7% across 10 years. Compounded, revenue has grown -40.1% a year over five years, -20.6% over three, —% over the last twelve months. Net profit fell to $-140.0M.

Operating margin went from -182.2% in 2016 to -10386.5% in 2025, a fall of 10204.4 percentage points. The most recent net margin is -14000.00%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-138.0M.

Borrowings rose from $19.0M to $107.0M, cash from operations was $-130.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -289.1% over five years, and was -1750.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Inhibrx Biosciences, Inc. (INBX) — frequently asked questions